Literature DB >> 21960779

Refractory ulcerative colitis treatment.

Richard P Macdermott1, Jesse A Green.   

Abstract

Treatment of refractory ulcerative colitis (UC) is a common clinical challenge. In either acute or chronic refractory UC, the disease may continue to remain active, even though the patient is on appropriate therapy. It is important to reassess and characterize the patient's disease before adding new medications to the current medical regimen. After determining the current extent and severity of the UC-ruling out other causes of bloody diarrhea and determining what complications are present-new treatment approaches can then be started. It is critical to first optimize oral 5-aminosalicylic acid (5-ASA) therapy combined with rectal 5-ASA or corticosteroid suppositories, plus corticosteroid or 5-ASA enemas or foam preparations. Oral or intravenous corticosteroids are appropriate to use if needed, but alternative approaches must be used for long-term maintenance. 6-Mercaptopurine (6-MP) or azathioprine can be very helpful for severe chronic refractory UC. In those patients who do not respond to 5-ASA medications, corticosteroids, and 6-MP or azathioprine, infliximab offers an important approach for induction and maintenance of remission for refractory chronic ulcerative colitis as well as for select cases of refractory acute UC. Cyclosporine use is an alternative medical approach for the refractory acute UC patient. Colectomy with ileal pouch-anal anastomosis remains a valuable option for the refractory chronic or acute UC patient, because it can provide both a "cure" for the disease, as well as eliminate ineffective medications with their associated side effects.

Entities:  

Keywords:  5-ASA; 6-MP; Ulcerative colitis; azathioprine; corticosteroids; cyclosporine; infliximab

Year:  2007        PMID: 21960779      PMCID: PMC3096121     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  37 in total

1.  Cyclosporin for refractory ulcerative colitis.

Authors:  C G Loftus; E V Loftus; W J Sandborn
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

2.  Guidelines for the management of inflammatory bowel disease in adults.

Authors:  M J Carter; A J Lobo; S P L Travis
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.

Authors:  Asher Kornbluth; David B Sachar
Journal:  Am J Gastroenterol       Date:  2004-07       Impact factor: 10.864

4.  Cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  R Vega; X Bertrán; M Menacho; E Domènech; V Moreno de Vega; M Hombrados; E Cabré; I Ojanguren; M A Gassull
Journal:  Am J Gastroenterol       Date:  1999-04       Impact factor: 10.864

5.  A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.

Authors:  M Safdi; M DeMicco; C Sninsky; P Banks; L Wruble; J Deren; G Koval; T Nichols; S Targan; C Fleishman; B Wiita
Journal:  Am J Gastroenterol       Date:  1997-10       Impact factor: 10.864

6.  Infliximab for refractory ulcerative colitis.

Authors:  W Y Chey; A Hussain; C Ryan; G D Potter; A Shah
Journal:  Am J Gastroenterol       Date:  2001-08       Impact factor: 10.864

7.  Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Authors:  B E Sands; W J Tremaine; W J Sandborn; P J Rutgeerts; S B Hanauer; L Mayer; S R Targan; D K Podolsky
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325

8.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

9.  Cyclosporine in severe ulcerative colitis refractory to steroid therapy.

Authors:  S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer
Journal:  N Engl J Med       Date:  1994-06-30       Impact factor: 91.245

10.  The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.

Authors:  J George; D H Present; R Pou; C Bodian; P H Rubin
Journal:  Am J Gastroenterol       Date:  1996-09       Impact factor: 10.864

View more
  4 in total

1.  Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice.

Authors:  Hai-Tao Xiao; Jiao Peng; Dong-Dong Hu; Cheng-Yuan Lin; Bin Du; Siu-Wai Tsang; Ze-Si Lin; Xiao-Jun Zhang; Feng-Ping Lueng; Quan-Bin Han; Zhao-Xiang Bian
Journal:  Chin Med       Date:  2015-10-13       Impact factor: 5.455

2.  Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures.

Authors:  Shelly R Gunn; G Gibson Gunn; Francis W Mueller
Journal:  Am J Case Rep       Date:  2016-05-11

Review 3.  Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome.

Authors:  Israr Khan; Naeem Ullah; Lajia Zha; Yanrui Bai; Ashiq Khan; Tang Zhao; Tuanjie Che; Chunjiang Zhang
Journal:  Pathogens       Date:  2019-08-13

4.  Subtotal colectomy in ulcerative colitis-long term considerations for the rectal stump.

Authors:  Orla Hennessy; Laurence Egan; Myles Joyce
Journal:  World J Gastrointest Surg       Date:  2021-02-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.